A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1089

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: Intismeran autogene
BIOLOGICAL: Pembrolizumab
OTHER: Placebo

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]